BANK1 and breast carcinoma: For example, upregulation or deletion of BANK1 was found to affect treatment outcomes in a clinical trial of irinotecan combined with rituximab for cell lymphoma, which may be related to the intervention of immune inflammatory mechanisms by drugs affecting BANK1 expression (Wang et al., 2022; Yang et al., 2018); A study on the mechanism of epithelial-mesenchymal transition and CDK4/6 inhibitor resistance in breast cancer found that CADM2 expression affects disease progression and drug efficacy, and its expression may be indirectly affected by quercetin (Li et al., 2024).